Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
June 14th, 2024
Here we present a protocol for the generation and functional verification of hypoxia-sensitive chimeric antigen receptor (CAR)-T cells. This protocol presents the lentivirus-based generation of hypoxia-sensitive CAR-T cells and their characterization, including the validation of hypoxia-dependent CAR expression and selective cytotoxicity.
Our research primarily focuses on cancer immunotherapy, particularly in CAR T-cell-based immunotherapy. We have been exploring novel strategies during last 10 years to enable CAR T-cells to specifically target a tumor with minimizing the side effect or even no side effect at all. Novel strategy have been persistently explored to improve the safety and efficacy of the CAR T-cell-based immunotherapy, in particularly by targeting tumor microenvironment, such as hypoxia-conditioned CAR, as exemplified in this protocol.
Interestingly, recent study demonstrated that hypoxia-condition CAR T not only greatly improved the safety profile, but also reduced the CAR T exhaustion and enhanced the efficacy in solid tumors. Hypoxia is a characteristic feature of tumor microenvironment. Our research aims to help researchers in the field of cancer immunotherapy understand the concept of hypoxia-sensitive CAR T-cells, their construction and how to establish hypoxia models for evaluation.
Our laboratory will continue exploring new strategies for constructing CAR T-cells to enhance their tumor-curing efficacy, safety profile and cost effectiveness.
Overview
This article presents a protocol for generating hypoxia-sensitive chimeric antigen receptor (CAR)-T cells and verifying their functionality. The focus is on the lentivirus-based generation of these CAR-T cells, emphasizing their hypoxia-dependent expression and selective cytotoxicity against tumors.
Key Study Components
Area of Science
- Cancer Immunotherapy
- Chimeric Antigen Receptor (CAR) Technology
- Hypoxia in Tumor Microenvironment
Background
- CAR T-cell therapy is a promising approach in cancer treatment.
- Hypoxia is a common feature of the tumor microenvironment that can affect therapy outcomes.
- Improving the safety and efficacy of CAR T-cells is crucial for better patient outcomes.
- This research explores hypoxia-sensitive CAR T-cells as a novel strategy.
Purpose of Study
- To develop a protocol for creating hypoxia-sensitive CAR-T cells.
- To validate the functionality of these CAR-T cells in hypoxic conditions.
- To enhance understanding of CAR T-cell behavior in the tumor microenvironment.
Methods Used
- Lentivirus-based generation of CAR-T cells.
- Characterization of CAR expression under hypoxic conditions.
- Assessment of selective cytotoxicity against tumor cells.
- Establishment of hypoxia models for evaluation.
Main Results
- Successful generation of hypoxia-sensitive CAR-T cells.
- Validation of hypoxia-dependent CAR expression.
- Demonstration of selective cytotoxicity in hypoxic environments.
- Improved safety profile and efficacy in solid tumors.
Conclusions
- Hypoxia-sensitive CAR-T cells represent a promising advancement in cancer immunotherapy.
- This protocol can aid researchers in developing safer and more effective CAR-T therapies.
- Understanding hypoxia's role in CAR T-cell function is essential for future research.
